Canaccord Genuity Maintains a 'Buy' on BioMimetic Therapeutics (BMTI); Q3/11 Results Provide Little Clarity Into FDA Mindset for Augment
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Price: $9.49 --0%
Rating Summary:
0 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
0 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on BioMimetic Therapeutics (NASDAQ: BMTI) price target of $13.00.
Canaccord analyst, William J. Plovanic, said, "We maintain our rating on BioMimetic following Q3/11 results. We note that no update on the Augment PMA application was provided. Management continues to wait for an official response letter from the FDA following Augment’s Q2/11 panel meeting. Additionally, proposed changes to the AIBG pivotal trial size is expected to increase trial costs by ~50% and delays expected completion of enrolment until the H2/12."
For an analyst ratings summary and ratings history on BioMimetic Therapeutics click here. For more ratings news on BioMimetic Therapeutics click here.
Shares of BioMimetic Therapeutics closed at $3.19 yesterday.
Canaccord analyst, William J. Plovanic, said, "We maintain our rating on BioMimetic following Q3/11 results. We note that no update on the Augment PMA application was provided. Management continues to wait for an official response letter from the FDA following Augment’s Q2/11 panel meeting. Additionally, proposed changes to the AIBG pivotal trial size is expected to increase trial costs by ~50% and delays expected completion of enrolment until the H2/12."
For an analyst ratings summary and ratings history on BioMimetic Therapeutics click here. For more ratings news on BioMimetic Therapeutics click here.
Shares of BioMimetic Therapeutics closed at $3.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mesoblast completes patient treatment in phase 3 back pain trial
- KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
